Posts by: Joana Carvalho

Joana Carvalho

May 24, 2019

Oncopeptides Prepares NDA for Accelerated Approval of Ygalo as Treatment for Refractory Multiple Myeloma

News

Oncopeptides is preparing to submit a new drug application (NDA) with the U.S. Food and Drug Administration (FDA) to seek accelerated approval of Ygalo (melflufen) to treat patients with triple-refractory ... Read more

May 8, 2019

Allogene’s CAR T-cell Therapy Triggers Durable Anti-Tumor Response in Animal Model

News

ALLO-715, Allogene Therapeutics‘ donor-derived CAR T-cell therapy, can trigger a durable anti-tumor response in mice with multiple myeloma, and maintain its characteristics and anti-tumor activity after large-scale manufacturing, a study ... Read more

April 29, 2019

Ninlaro Maintenance Therapy Prolongs and Boosts Treatment Benefits in Myeloma Patients, Study Says

News

Maintenance therapy with Ninlaro (ixazomib) can prolong and boost therapeutic responses from initial treatment in multiple myeloma patients who did not undergo an autologous stem cell transplant, a study says. The ... Read more

April 3, 2019

European Panel OKs Approval of Triple Combination Therapies for Multiple Myeloma Patients

News

The European Medicines Agency‘s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Celgene‘s Revlimid (lenalidomide) and Pomalyst (pomalidomide, marketed as Imnovid in Europe) as combination therapies ... Read more

March 14, 2019

CARsgen to Begin CT053 Clinical Testing in China for Heavily Treated Myeloma Patients

News

CT053, one of CARsgen Therapeutics‘ lead CAR T-cell therapies, soon will begin clinical testing in China for the treatment of patients with relapsed or refractory multiple myeloma, after the Chinese ... Read more

March 8, 2019

FDA Raises Concerns on Safety, Tolerability of Potential Myeloma Therapy Selinexor

News

The U.S. Food and Drug Administration has raised concerns in its newly released briefing materials over the safety and tolerability of Karyopharm Therapeutics‘ lead compound selinexor, creating a potential stumbling block on its path ... Read more

October 26, 2018October 26, 2018

Revlimid Delays Disease Progression in Smoldering Myeloma Patients, Preliminary Trial Results Show

News

Celgene‘s immunomodulatory agent Revlimid (lenalidomide) significantly extended the time until disease progression in patients with smoldering multiple myeloma who were not yet experiencing any symptoms of disease, according to Phase 2/3 results ... Read more

October 24, 2018

Darzalex Add-on Increases Complete Responses After Stem Cell Transplant, Phase 3 Myeloma Trial Shows

News

Adding Darzalex (daratumumab) to the standard pre-transplant therapy for multiple myeloma significantly increased the number of patients showing no signs of cancer after a stem cell transplant, a Phase ... Read more

October 8, 2018

Takeda, Molecular Templates Partner to Develop Next-generation IO for Multiple Myeloma

News

Molecular Templates has partnered with Takeda to develop engineered toxin bodies (EBTs) — a next-generation immuno-oncology therapy that delivers toxic payloads to cancer cells — targeting the CD38 molecule as a potential treatment for multiple myeloma. ... Read more

September 10, 2018

Some with Smoldering Multiple Myeloma May Benefit from Immediate Treatment, Study Suggests

News

Smoldering multiple myeloma (SMM) — an early, asymptomatic precursor of multiple myeloma — often exhibits similar genetic alterations as the full-blown disease, suggesting that patients could benefit from prompt treatment instead ... Read more

Pin It on Pinterest